Kevin Petrie

4.3k total citations · 1 hit paper
41 papers, 1.6k citations indexed

About

Kevin Petrie is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Kevin Petrie has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 15 papers in Hematology and 6 papers in Oncology. Recurrent topics in Kevin Petrie's work include Acute Myeloid Leukemia Research (15 papers), Histone Deacetylase Inhibitors Research (14 papers) and Retinoids in leukemia and cellular processes (12 papers). Kevin Petrie is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Histone Deacetylase Inhibitors Research (14 papers) and Retinoids in leukemia and cellular processes (12 papers). Kevin Petrie collaborates with scholars based in United Kingdom, United States and Germany. Kevin Petrie's co-authors include Arthur Zelent, Samuel Waxman, Louise Howell, Tino Schenk, Louis Chesler, Fabien Guidez, John Anderson, Mel Greaves, Mark D. Minden and Andreea C. Popescu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Kevin Petrie

40 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

2012 502 citations Tino Schenk, Louise Howell et al. profile →

Peers

Countries citing papers authored by Kevin Petrie

Since Specialization

Citations

This map shows the geographic impact of Kevin Petrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Petrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Petrie more than expected).

Fields of papers citing papers by Kevin Petrie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Petrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Petrie. The network helps show where Kevin Petrie may publish in the future.

Co-authorship network of co-authors of Kevin Petrie

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Petrie. A scholar is included among the top collaborators of Kevin Petrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Petrie. Kevin Petrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells 2023 ·Frontiers in Cell and Developmental Biology ·Yordan Sbirkov, Tino Schenk, Colin Kwok, Sven Stengel, Robert Brown, G. E. Brown, Louis Chesler, Arthur Zelent, Matthew J. Fuchter, Kevin Petrie	9
2	Targeting Glutaminolysis Shows Efficacy in Both Prednisolone-Sensitive and in Metabolically Rewired Prednisolone-Resistant B-Cell Childhood Acute Lymphoblastic Leukaemia Cells 2023 ·International Journal of Molecular Sciences ·Yordan Sbirkov, (unknown), (unknown), Tino Schenk, Kevin Petrie, Victoria Sarafian	3
3	Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia 2022 ·British Journal of Haematology ·Sven Stengel, Kevin Petrie, Yordan Sbirkov, (unknown), (unknown), Veronica Gil, (unknown), Paweł Kamiński, Łukasz Szymański, Annamaria Brioli, Arthur Zelent, Tino Schenk	17
4	The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme 2021 ·Cancer Gene Therapy ·Zuzanna Urban‐Wójciuk, Amy C. Graham, Karen Barker, Colin Kwok, Yordan Sbirkov, Louise Howell, James Campbell, Patrick M. Woster, Evon Poon, Kevin Petrie, Louis Chesler	4
5	The Protozoan Inhibitor Atovaquone Affects Mitochondrial Respiration and Shows In Vitro Efficacy Against Glucocorticoid-Resistant Cells in Childhood B-Cell Acute Lymphoblastic Leukaemia 2021 ·Frontiers in Oncology ·Yordan Sbirkov, (unknown), (unknown), (unknown), Kevin Petrie, Tino Schenk, (unknown)	5
6	Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer 2020 ·Cancer Reports ·Kevin Petrie, Zuzanna Urban‐Wójciuk, Yordan Sbirkov, (unknown), (unknown), G. E. Brown	19
7	The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML 2019 ·Leukemia ·(unknown), Annamaria Brioli, Martin Bens, Florian Perner, (unknown), Ulf Schnetzke, (unknown), Yordan Sbirkov, Sven Stengel, Giorgia Simonetti, Giovanni Martinelli, Kevin Petrie, Arthur Zelent, (unknown), Marco Groth, Thomas Ernst, Florian H. Heidel, Sebastian Scholl, Andreas Hochhaus, Tino Schenk	29
8	Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase 2017 ·International Journal of Molecular Sciences ·Yordan Sbirkov, Colin Kwok, Amandeep Bhamra, Andrew Thompson, Veronica Gil, Arthur Zelent, Kevin Petrie	7
9	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance 2016 ·Cancer Research ·Orli Yogev, Karen Barker, (unknown), Gilberto S. Almeida, Albert Hallsworth, Laura Smith, Yann Jamin, Ruth Ruddle, Alexander Koers, Hannah Webber, Florence I. Raynaud, Sergey Popov, Chris Jones, Kevin Petrie, Simon P. Robinson, Hector C. Keun, Louis Chesler	32
10	Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma 2016 ·Disease Models & Mechanisms ·Veronica Gil, Govind Bhagat, Lydia Pleotis Howell, Jing Zhang, Chong Kim, Sven Stengel, Francisco Vega, Arthur Zelent, Kevin Petrie	39
11	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma 2015 ·Clinical Cancer Research ·M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, (unknown), Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin Petrie, Rolf W. Sparidans, Robbert J. Kok, Rogier Versteeg, Huib N. Caron, Louis Chesler, Jan J. Molenaar	47
12	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity 2015 ·Cancer Research ·Francis Mussai, Sharon A. Egan, Stuart Hunter, Hannah Webber, Jonathan Fisher, Rachel Wheat, Carmel McConville, Yordan Sbirkov, Kate Wheeler, Gavin Bendle, Kevin Petrie, John Anderson, Louis Chesler, Carmela De Santo	84
13	HDAC9 Expression Is Deregulated in Malignant B-Cell Lymphomas in Particular in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma 2014 ·Blood ·Elena Cubedo, Veronica Gil, Chae Hwa Kim, Germán Campuzano‐Zuluaga, Nitin Agarwal, Louise Howell, Kevin Petrie, Francisco Vega, Arthur Zelent	1
14	CREATIVE GLASS RESEARCHCase studies from art and design 2011 ·Biopolymers ·Kevin Petrie	2
15	Differentiation therapy of acute myeloid leukemia: past, present and future 2009 ·Current Opinion in Hematology ·Kevin Petrie, Arthur Zelent, Samuel Waxman	135
16	Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters 2008 ·Oncogene ·Kevin Petrie, Fabien Guidez, Jiang Zhu, Louise Howell, Gareth I. Owen, (unknown), (unknown), Susannah Waxman, Jonathan D. Licht, Sibylle Mittnacht, Arthur Zelent	8
17	Derepression in the Desert: The Third Workshop on Clinical Translation of Epigenetics in Cancer Therapeutics 2008 ·Cancer Research ·Arthur Zelent, Kevin Petrie, Manuel Boix-Chornet, Ari Melnick, Samuel Waxman, Steven D. Gore	6
18	Histone Deacetylase Inhibitors in APL and Beyond 2007 ·Current topics in microbiology and immunology ·Kevin Petrie, (unknown), Arthur Zelent	6
19	Glass and Print 2006 ·Bloomsbury Publishing Plc eBooks ·Kevin Petrie	3
20	The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms 2003 ·Journal of Biological Chemistry ·Kevin Petrie, Fabien Guidez, Louise Howell, Lyn Healy, Samuel Waxman, Mel Greaves, Arthur Zelent	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact